Table 1:
Clinical and pathologic characteristics of 289 individuals with resected pancreatic adenocarcinoma
| Overall | Pathogenic or likely pathogenic germline variant | |||
|---|---|---|---|---|
| Yes | No | P-valuea | ||
| Number of subjects | 289 | 28 | 261 | |
| Women (n, %) | 138 (48%) | 14 (50%) | 124 (48%) | 0.84 |
| Median age at diagnosis, years, (IQR) | 67 (15) | 66 (17) | 67 (14) | 0.77b |
| Center (n, %) | ||||
| DF/BWCC | 93 (32%) | 13 (46%) | 80 (31%) | 0.22 |
| URMC | 80 (28%) | 8 (29%) | 72 (27%) | |
| SCI | 116 (40%) | 7 (25%) | 109 (42%) | |
| Racial background (n, %) | ||||
| White | 220 (76%) | 23 (82%) | 197 (75%) | 0.66 |
| Black | 4 (1%) | - | 4 (2%) | |
| Asian | 28 (10%) | 1 (4%) | 27 (10%) | |
| Unknown | 37 (13%) | 4 (14%) | 33 (13%) | |
| Tumor location (n, %) | ||||
| Head/Uncinate | 213 (74%) | 14 (50%) | 199 (76%) | 0.01 |
| Body | 28 (10%) | 2 (7%) | 26 (10%) | |
| Tail | 41 (14%) | 11 (39%) | 30 (12%) | |
| Overlapping sites | 7 (2%) | 1 (4%) | 6 (2%) | |
| pT stage (n, %) | ||||
| T1–T2 | 46 (16%) | 4 (14%) | 42 (16%) | 1.00 |
| T3–T4 | 242 (83%) | 24 (86%) | 218 (83%) | |
| Tx | 1 (1%) | - | 1 (1%) | |
| pN stage (n, %) | ||||
| N0 | 75 (26%) | 9 (32%) | 66 (25%) | 0.50 |
| N1 | 213 (73%) | 19 (68%) | 194 (74%) | |
| Nx | 1 (1%) | - | 1 (1%) | |
| Tumor differentiation (n, %) | ||||
| Well/Moderately | 160 (55%) | 16 (57%) | 144 (55%) | 0.84 |
| Poorly/Undifferentiated | 123 (43%) | 11 (39%) | 112 (43%) | |
| Unknown | 6 (2%) | 1 (4%) | 5 (2%) | |
| Lymphovascular invasion (n, %) | ||||
| Present | 137 (47%) | 11 (39%) | 126 (48%) | 0.23 |
| Absent | 126 (44%) | 16 (57%) | 110 (42%) | |
| Unknown | 26 (9%) | 1 (4%) | 25 (10%) | |
| Resection margin status (n, %) | ||||
| R0 | 138 (48%) | 12 (43%) | 126 (48%) | 0.73 |
| R1 | 146 (50%) | 16 (57%) | 130 (50%) | |
| R2 | 3 (1%) | - | 3 (1%) | |
| Rx (not evaluable) | 2 (1%) | - | 2 (1%) | |
| First site of recurrence (n, %) | ||||
| Local only | 44 (15%) | 3 (11%) | 41 (16%) | 0.71 |
| Distant only | 108 (37%) | 10 (35%) | 98 (38%) | |
| Synchronous local and distant | 42 (15%) | 5 (18%) | 37 (14%) | |
| No known recurrence | 68 (24%) | 7 (25%) | 61 (23%) | |
| Unknown | 27 (9%) | 3 (11%) | 24 (9%) | |
Abbreviations: DF/BWCC, Dana-Farber/Brigham and Women’s Cancer Center; URMC, University of Rochester Medical Center; SCI, Stanford Cancer Institute.
a
Calculated using Fisher exact test unless otherwise specified.
b
Calculated using Wilcoxon rank sum test.